197 related articles for article (PubMed ID: 12548357)
21. Structural changes in the midbrain with aging and Parkinson's disease: an MRI study.
Sohmiya M; Tanaka M; Aihara Y; Okamoto K
Neurobiol Aging; 2004 Apr; 25(4):449-53. PubMed ID: 15013565
[TBL] [Abstract][Full Text] [Related]
22. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.
Cho ZH; Oh SH; Kim JM; Park SY; Kwon DH; Jeong HJ; Kim YB; Chi JG; Park CW; Huston J; Lee KH; Jeon BS
Mov Disord; 2011 Mar; 26(4):713-8. PubMed ID: 21506148
[TBL] [Abstract][Full Text] [Related]
23. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
24. [Importance of magnetic resonance in Parkinson disease. An analytic study of the pars compacta].
Maurício JC; Coelho H; Sá J; Martins A
Acta Med Port; 1990; 3(2):85-8. PubMed ID: 2349893
[TBL] [Abstract][Full Text] [Related]
25. Iron-dependent enzymes in Parkinson's disease.
Reichmann H; Janetzky B; Riederer P
J Neural Transm Suppl; 1995; 46():157-64. PubMed ID: 8821051
[TBL] [Abstract][Full Text] [Related]
26. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging of the midbrain in Parkinson's disease.
Duguid JR; De La Paz R; DeGroot J
Ann Neurol; 1986 Dec; 20(6):744-7. PubMed ID: 3813504
[TBL] [Abstract][Full Text] [Related]
28. T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome.
Astrakas LG; Konitsiotis S; Margariti P; Tsouli S; Tzarouhi L; Argyropoulou MI
Neurology; 2008 Sep; 71(12):911-6. PubMed ID: 18794493
[TBL] [Abstract][Full Text] [Related]
29. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
[TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
31. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
32. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
Kashihara K; Shinya T; Higaki F
J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
[TBL] [Abstract][Full Text] [Related]
33. Potential role of high-field MRI for studies in Parkinson's disease.
Schuff N
Mov Disord; 2009; 24 Suppl 2():S684-90. PubMed ID: 19877239
[TBL] [Abstract][Full Text] [Related]
34. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance.
Ye FQ; Allen PS; Martin WR
Mov Disord; 1996 May; 11(3):243-9. PubMed ID: 8723139
[TBL] [Abstract][Full Text] [Related]
35. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
36. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease.
Salehi Z; Mashayekhi F
J Clin Neurosci; 2009 Jan; 16(1):90-3. PubMed ID: 19017558
[TBL] [Abstract][Full Text] [Related]
37. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
38. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
Andersen JK
Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
[TBL] [Abstract][Full Text] [Related]
39. Detrimental deletions: mitochondria, aging and Parkinson's disease.
Biskup S; Moore DJ
Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
[TBL] [Abstract][Full Text] [Related]
40. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
